Summary A phase I trial was conducted with lobaplatin (D-19466; 1,2-diamminomethyl-cyclobutaneplatinum (II)-lactate) i.v. bolus daily for 5 days every 4 weeks. After entering five patients toxicity appeared to be related to renal function, therefore the individual dose (total dose 20-100 mg m2 over 5 days) of lobaplatin was modified according to creatinine clearance (CRCL) and escalated in patients. Twenty-seven patients with refractory solid tumours received 72 courses. Thrombocytopenia was dose-limiting, its degree was related to dose and CRCL at time of drug administration. With a CRCL of 60-80mlmin-' the maximum tolerated dose was 40mgm-2, with a CRCL of 81-100mlmin-' 70mg m-2, and with a CRCL>100mlmin-' it was 85mgm-2. Platelet and leukocyte nadirs were observed around day 21. The percentual platelet nadir (percentage of day 1 platelet count) correlated with CRCL at different dose levels and could be described by 0.76 x CRCL (ml min-') -{1.45 x dose (mg m-2) + 43.38. This equation tested in 20 patients (28 courses) produced a correlation between observed and predicted percentual platelet nadir (r = 0.82, P<O0.001). No renal function impairment occurred. Urinary excretion of platinum (by A.A.S.) was estimated in six patients and revealed that 91.5% (s.e. ± 7.9) of the platinum dose was excreted within 4 h. Responses (one PR, one CR) occurred in two patients with ovarian cancer (both pretreated with carboplatin and cisplatin).
The recommended dose of lobaplatin i.v. bolus daily for 5 days for phase II studies depends on renal function, namely 30mgm-2 at CRCL 60-80mlmin-'; 55mgm-2 at CRCL 81 -00 mlmin-'; 70mgm-2 at CRCL > 100 ml minCis-Diamminedichloro-platinum (II) (cisplatin) has had a major impact on the improvement of cancer treatment (Rosenberg et al., 1969) . This compound is one of the key drugs in the treatment of solid tumours such as germ-cell cancer, ovarian cancer, bladder cancer and bronchial carcinoma (Einhorn & Donahue, 1977; Wiltshaw & Kroner, 1976; Soloway, 1978; Gralla et al., 1979) . The severity of renal, neuro, and gastrointestinal toxicity associated with cisplatin administration encouraged the development of alternative platinum compounds with a better therapeutic index. Cisdiammine 1,1-cyclobutane-dicarboxylato-platinum (Carboplatin) has emerged as a leading analogue demonstrating a highly reduced emetic and nephrotoxic effect while preserving almost the same efficacy as cisplatin (Mangioni et al., 1989; Bajorin et al., 1991) . Myelosuppression is considered to be the dose limiting toxicity of carboplatin. Complete crossresistance between the two drugs is however the rule and as a consequence their spectrum of antitumour activity is comparable Canetta et al., 1988) .
Lobaplatin (D-19466; 1, 2-diamminomethyl-cyclobutaneplatinum (II)-lactate) (Figure 1 ) was synthesised as a representative of platinum derivatives of the third generation. Lobaplatin showed a markedly higher antitumour effect in vitro toward B16 melanoma and AH13s hepatoma compared with cisplatin (Voegeli et al., 1990) . This was also implied by experiments performed in two cell lines and their cisplatin resistant sublines. In one line, a small cell lung carcinoma cell line (GLC4 and its resistant subline GLC4-CDDP), lobaplatin showed full cross resistance, whereas in another line, a human embryonal cancer cell line (Ntera2/D1 and its cisplatin resistant subline tera-CP), lobaplatin demonstrated no cross resistance (Meijer et al., 1991) . In vivo, in mice bearing the P388 leukaemia, administration of lobaplatin resulted in a higher increase of life span compared with equitoxic doses of cisplatin or carboplatin. In a cisplatin resistant P388, tumour in which neither cisplatin nor carboplatin were able to inhibit the proliferation after transplantation, the survival of the animals was significantly prolonged by lobaplatin (Voegeli et al., 1990) . These preclinical data are suggestive for the lack of cross-resistance of lobaplatin in a number of platinum resistance tumour models.
After (WHO handbook, 1978 ) the subsequent course in those same patients was given at the next dose level, and escalation was continued in that way. If toxicity exceeded grade 2, a deescalation to the previous dose level was performed. In case of grade 2 toxicity the next course was given at the same dose. This approach would limit the number of patients to be treated at inactive dose levels, as all patients could reach the ultimate dose. The chance that cumulative toxicity would interfere with the dose finding was circumvented by entering three to six new patients at the first dose level found to be toxic (WHO grade 2). The initial dose levels for this study, chosen with a modified Fibonacci search system (Hansen et al., 1971) , were 20-40-70-100mgm-2 (total dose per 5 days). After administering 11 courses of lobaplatin to the first five patients entered in this study we became aware of the possible relation between the hematological toxicity and the CRCL of the patients at time of the lobaplatin administration. Based on these data the starting dose of subsequent patients for further dose escalation was adjusted to CRCL at entrance of this study. Two 24-h urinary clearances were measured within 1 week prior to treatment, the mean of these two CRCL values was used to determine lobaplatin starting dosage. Patients with a CRCL between 60 and 80 ml min'-started at 30mg m2, with a CRCL between 81 and 100 ml min-' started at 40 mg m2 and patients with a CRCL above 100 ml min-' started at 70 mg m-2 Lobaplatin. Additional dose levels of lobaplatin added to the initial escalation scheme were 30, 55, and 85 mg m-2. Escalation and deescalation methods remained the same as mentioned above. The MTD was defined as the dose at which any parameter reached WHO grade 3 or 4 toxicity in three patients.
During each 28 day course complete blood cell count, electrolytes, liver and renal function, and glucose were measured on each treatment day and on day 14, 21, and 28. Twenty-four-hour urinary creatinine clearances were performed twice before study entry, twice prior to each lobaplatin course, on each treatment day and on day 14 of each course. The CRCL before study entry and during lobaplatin treatment were done while patients were hospitalised to ensure complete urine collection. ECG and chest X-rays were done before each course of lobaplatin.
To be evaluable for response the patient with measurable disease had to receive at least two courses of lobaplatin. CRCL between 60 and 80 ml min-'. At 70 mg m-2 thrombocytopenia grade 3/4 occurred in six out of seven patients with a CRCL between 81 and 100 ml min-', and was therefore the maximum tolerable dose. In one patient this was accompanied by a grade 3 leukocytopenia. In patients with a CRCL above lOOml min-' 85 mg m2 was found to be the MTD. Grade 4 thrombocytopenia was encountered in three out of four patients treated at this dose level, accompanied in two by a grade 3 leukocytopenia. Twenty-three of all patients reached the maximum administered dose level during their first or second course of lobaplatin. All except three patients were pretreated with chemotherapy, so the influence of previous treatment on hematologic toxic effects of lobaplatin could not be evaluated. The median time to platelet count nadir was 21 days (range 14 to 28), the median time to leukocyte count nadir was 19 days (range 6 to 28). The median time to recovery of the platelet counts was 7 days (range 2 to 18), the median time to recovery of leucocyte counts was 7 days (range 1 to 18). The blood count recovery was not different when the first course was compared with the second or third course. Six of 23 patients receiving multiple courses of lobaplatin required postponement of a course, all because of not fully recovered leukocyte count. Patients escalating to higher dose levels had no more myelosuppression than new patients entered at these levels. From patients treated with three or more courses lobaplatin on the same (Figure 2 ). Non hematological toxicity was confined to mild nausea and emesis (Table V) . Patients tended to experience grade 2 nausea when they reached their maximum tolerable dose according to the renal function cohort they belonged to. (Table V) . The gastrointestinal adverse toxic effects of lobaplatin could be completely abrogated by the 5-HT3 receptor antagonist ondansetron. Antiemetics were administered to nine patients, only after they experienced WHO grade 2 nausea and vomiting. No changes in CRCL or serum creatinine were observed during treatment with lobaplatin. In patients who received multiple courses lobaplatin (n = 23), the mean CRCL before the first and after the last treatment course was 101 ± 28 and 99 ± and 24 ml min-', respectively (P> 0.3); the mean serum creatinine before the first and after the last course was 74 ± 17 and 80 ± 18 tsmol 1', respectively (NS). One patient with a colon carcinoma with liver metastases and progressive disease during treatment, developed proteinuria (maximal 3 g per 24 h) during her second course. This selective proteinuria did not alter after the third and last course. No other signs of renal toxicity were observed during this trial. One patient with a soft tissue sarcoma of the stomach with regional progression in the liver developed during her third course of lobaplatin liver function disturbances (WHO grade 2) with an elevation of alkaline phosphatase and T-glutamyl transferase without signs of tumour progression. The liver function disturbances disappeared after lobaplatin was stopped, and may therefore be related to the trial drug. No other signs of hepatic toxicity were observed. None of the patients developed alopecia. There was no evidence of neurotoxicity during this study. At entry four patients had paresthesias due to previous cisplatin treatment, none of them experienced a deterioration of the paresthesias 
Pharmacokinetics
The kidney was the major route of excretion. After 4 h most of the platinum injected had been excreted in the urine (mean 91.5%; range 66 to 113) (Figure 3 ). The pattern of excretion was similar at different dose levels tested. No correlation could be detected between CRCL and the amount of platinum excreted in the urine. In three patients urinary excretion of platinum was measured both on day 1 and day 5 of lobaplatin administration. In all three cases measurements on day 5 were similar with those on day 1. 
Discussion
Lobaplatin was introduced in clinical trials because of its limited toxicity while in preclinical tumour systems it showed promising antitumour activity in cell lines and xenografts resistant to cisplatin (Voegeli et al., 1990; Meijer et al., 1991) . The results of this clinical phase I trial indicate that some of these expectations may be fulfilled. Lobaplatin is a well tolerated drug with predictable dose-related side effects. Careful monitoring of toxicity revealed after entering five patients that the dose-limiting toxicity was thrombocytopenia and that it was related to CRCL. Dose limiting thrombocytopenia occurred at different dosages lobaplatin in the three distinct CRCL cohorts that patients were entered into: 60-80, 81-100, and >I00 mlmin-', and were 40, 70, and 85 mg m-2, respectively. Thrombocytopenia was marked but short of duration. The nausea and vomiting in this Lobaplatin daily times 5 schedule was mild, dose related and predominantly occurred in patients, pretreated with cis-or carboplatin. No decreases in renal function expressed in creatinine clearance were detected in any of the patients treated with Lobaplatin, therefore the drug is probably not nephrotoxic. Overall, the toxicity profile of Lobaplatin observed in this phase I trial resembles that of a carboplatin daily for 5 days schedule with hematological toxicity being dose limiting (Van Echo et al., 1984; Rozencweig et al., 1983) .
Egorin et al. (Egorin et al., 1984) found that the percentage reduction in platelet counts induced by carboplatin was correlated with the CRCL. With this observation they derived an equation with which the platelet nadir could be predicted. Furthermore Calvert et al. (Calvert et al., 1989) saw predictable hematological toxicity of carboplatin based on target area under the curve (AUC) and 51CrEDTA clearances in a prospective study. Another investigational platinum-complex 254-S was also found to induce a reduction in platelet counts that was related to renal function (Sasaki et al., 1990) . The rationale behind these relationships comes from the fact that the kidney is the major route of excretion of these platinum compounds. In the present study with a platinum compound also primarily excreted by the kidney we were able to establish a significant relation between the percentual platelet nadir count and the CRCL. This enabled us to derive an equation to predict the percentual platelet nadir (percentage of pretreatment platelet count). Testing this equation in 28 first or second courses of lobaplatin revealed a good correlation between the observed and predicted percentual platelet nadir. Because most of the patients studied in deriving this formula were pretreated with chemotherapy, we were not able to make a correction, such as described by Egorin et al. (Egorin et al., 1984) , for chemotherapy naive patients. Rearrangement of this relationship yielded the following equation with which to calculate lobaplatin dosages (total dose over 5 days) for pretreated patients with given CRCL's and desired platelet nadirs.
Dose Lobaplatin (mg m-2) = 0.69 x {0.76 x CRCLplatelet nadir desired (pretreatment platelets x 100) + 43.38) Application of this equation is only valid when the CRCL is in the range studied by us (between 60 and 155 ml min-1). The potential utility of this equation has to be further evaluated in a prospective study. Its usefulness in patients with a CRCL below 60 ml min' has also yet to be established.
Urinary excretion of Lobaplatin was remarkably rapid with 91.5% (s.e. ± 7.9) of the platinum dose being excreted within 4 h. This was much faster than the excretion of platinum after administration of carboplatin (25 to 30% within 4 h) in a comparable regimen (Egorin et al., 1984) .
One of the most promising results from this trial were two responses seen in six evaluable patients with ovarian cancer. The patient with a PR could be marked as clinical completely resistant to platinum, with refractory disease after first line carboplatin based chemotherapy and tumour progression during second-line cisplatin based therapy. The second patient had shown partial resistance on her second platinum line, but had a prolonged complete remission on Lobaplatin. Therefore this study provides clinical evidence that Lobaplatin might at least in part be non-cross resistant with cisplatin and carboplatin. Further trials with lobaplatin are therefore warranted.
Based on the current trial, the recommended dose of lobaplatin for phase II studies with a daily times five bolus infusion depends on renal function; CRCL 60-80 ml min-': 30 mg m-2; CRCL 81-100mlmin-': 55 mg m-2; CRCL > 100 ml min-': 70mgm2.
